Accro Bioscience (Accropeutics), a clinical-stage biotech company focused on molecular mechanisms of regulated cell death and related pathogenesis in human diseases, todayannounced that it will present results from a Phase II clinical study evaluating AC-201, an oral, selective TYK2/JAK1 Inhibitor, in moderate-to-severe plaque psoriasis, at the European Academy of Dermatology & Venereology (EADV) Congress, being held September 17-20th, in Paris.
Details of the presentation are as follows:Abstract Type: Oral Presentation in the Late Breaking SessionsAbstract ID: LBA-5Abstract Title: Efficacy and Safety of a Selective Oral TYK2/JAK1 Inhibitor, AC-201, in Patients with Plaque Psoriasis: A Phase II, Randomized, Double-blinded, Placebo-Controlled TrialSession Title: D3T01.4FSession Room: Paris NordPresentation Time: 17:15 – 17:30 Friday, 19 September
About AC-201
AC-201is a novel, highly selective and potent oral small-molecule inhibitor of TYK2/JAK1 that binds to the pseudo kinase domain (JH2) of TYK2/JAK1, with minimal effect on the JAK2/JAK2 signaling pathway. Itis currently being developed to treat immune mediated inflammatory diseases such as psoriasis (PsO),non-infectious uveitis (NIU), and cutaneous lupus erythematosus (CLE). Phase 1 studies in healthy volunteers conducted in Australia and China demonstrated that AC-201 was generally safe and well-tolerated across all dose groups, with no adverse events (AEs) leading to discontinuation or serious adverse events (SAEs).
About Accro Bioscience
Accro Bioscience is a clinical-stage biotech company with a core focus on the molecular mechanisms of regulated cell death and related pathogenesis in human diseases. The company currently has three clinical-stage assets. AC-201, a selective TYK2/JAK1 inhibitor with therapeutic potential across a broad range of immune mediated inflammatory diseases, has completed a Phase 2 clinical trial in psoriasis with positive efficacy and safety readout. The RIPK2 inhibitor, AC-101, has completed the Phase 1 study in Australia and China with excellent safety and PK/PD data, and a Ph1b trial in UC patients is currently ongoing. The RIPK1 inhibitor, AC-003, obtained Orphan Drug Designation from the FDA, has completed the Phase 1 study in China and the United States, and is currently in a Phase 1b trial for the treatment of aGvHD patients. Accro Bioscience owns global rights of the assets with 25 patents issued in China, Japan, US, Korea and EU.
Media Contact:Jack XuAccro BioscienceInfo@accropeutics.com
https://c212.net/c/img/favicon.png?sn=CN65651&sd=2025-09-04
View original content:https://www.prnewswire.com/news-releases/accro-bioscience-to-present-phase-ii-data-of-ac-201-for-plaque-psoriasis-at-the-european-academy-of-dermatology–venereology-congress-2025-in-paris-302546533.html
SOURCE Accropeutics
https://rt.newswire.ca/rt.gif?NewsItemId=CN65651&Transmission_Id=202509040824PR_NEWS_USPR_____CN65651&DateId=20250904